Richy Agajanian has sold TOI and made no open-market buys since May 2022

Richy Agajanian, MD is a hematologist/oncologist and founding physician associated with The Oncology Institute of Hope and Innovation, where he also serves as a significant equity holder and 10% owner of The Oncology Institute, Inc. (NASDAQ: TOI).( SEC ownership filings and insider-trading records show that he has held millions of shares of TOI common stock and has reported major insider transactions, including large sales in 2021–2022 as a 10% beneficial owner.( In addition to his clinical and shareholder roles, he has been involved in TOI’s growth from a mission-driven oncology practice into a publicly traded cancer-care company.(

Dr. Agajanian is recognized as a cancer specialist in California and Nevada, practicing hematology/oncology and holding board certifications in medical oncology, hematology, and internal medicine.( He earned his medical degree from the University of California Irvine School of Medicine, completed his internal medicine residency at Olive View–UCLA Medical Center, and finished fellowship training in hematology and oncology through UCLA-affiliated programs, including Olive View–UCLA Medical Center and Cedars-Sinai Medical Center.( Before medical school, he graduated magna cum laude in physiology and neuroscience from the University of California San Diego.( He is a member of multiple professional societies in oncology and internal medicine and has authored research on topics such as Burkitt lymphoma, myelodysplastic syndromes, and acute chest syndrome.(

Written by Perplexity from public sources.